Discover unique market-leading data and insights into the Diabetes market. From the latest Diabetes industry reports and analysis to comprehensive market growth forecasts, trends and research.
Browse our full list of Diabetesmarket reports here.
Diabetic Nephropathy (DN) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape Diabetic Nephropathy (DN) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
$3,495 | August 2023
Diabetic Nephropathy (DN) Marketed and Pipeline Drugs Report Overview Diabetic Nephropathy (DN) is glomerular sclerosis and fibrosis caused by the metabolic and hemodynamic changes of diabetes mellitus (DM). It manifests as slowly progressive albuminuria with worsening hypertension and renal insufficiency. DN is the most common cause of nephrotic syndrome in adults and is also the most common cause of end-stage renal disease (ESRD) in the US, accounting for up to 80% of cases. Renal failure is particularly common in certain...
$1,950 | June 2023
Digital Marketing Trends in Type 2 Diabetes Report Overview Novo Nordisk's Ozempic.com achieved the highest total traffic across type 2 diabetes (T2D) patient brand sites in the US, with over 23 million visitors between April 2022–March 2023, followed by Eli Lilly's Trulicity.com and AstraZeneca's Farxiga.com. The highest proportion of traffic to branded patient T2D websites originated from direct sources, followed by organic. Novo Nordisk’s Rybelsus.com had the highest proportion of direct traffic. The Digital Marketing Trends in the Type 2...
Diabetic Macular Edema Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update Diabetic Macular Edema Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
$2,500 | May 2023
Diabetic Macular Edema Clinical Trials Market Report Overview The Diabetic Macular Edema Clinical Trials market research report provides an overview of Diabetic Macular Edema Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Macular Edema. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points...
Painful Diabetic Neuropathy Epidemiology Analysis and Forecast to 2031 Painful Diabetic Neuropathy Epidemiology Analysis and Forecast to 2031
$3,995 | February 2023
Painful Diabetic Neuropathy Market Report Overview The total prevalent cases of Painful Diabetic Neuropathy (PDN) were 7,472,695 cases in the seven major markets (7MM) in 2021 and are expected to achieve an AGR of more than 1% during 2021-2031. Diabetic neuropathy refers to a variety of syndromes that differ in clinical course, distribution, and fiber involvement. Symptoms of diabetic neuropathy vary widely from patient to patient, and some patients with diabetic neuropathy have no symptoms. The PDN market research report...
Type 2 Diabetes Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029 Type 2 Diabetes Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029
$10,995 | December 2022
Type 2 Diabetes (T2D) Market Report Overview The T2D market value for the 9 markets (9MM) was $45.9 billion in 2019. T2D is a chronic disease characterized by insulin resistance and pancreatic β-cell failure, as defined by the International Classification of Diseases 11th edition (ICD-11), with an underlying genetic predisposition heavily influenced by diet and lifestyle. This disease is a multi-causal, heterogeneous, and progressive cardiometabolic condition that is commonly associated with obesity, dyslipidemia, hypertension, inflammation, and endothelial dysfunction. The prevalence...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.